Navitas stock soars as company advances 800V tech for NVIDIA AI platforms
Investing.com - H.C. Wainwright has maintained its Buy rating and $15.00 price target on Vir Biotechnology (NASDAQ:VIR), currently trading at $4.79, following a meeting with company management on September 8. According to InvestingPro data, analyst targets for VIR range from $12 to $31, suggesting significant upside potential.
The research firm hosted Vir’s Senior Director of Investor Relations Rich Lepke and CFO Jason O’Byrne during H.C. Wainwright’s 27th Annual Global Investment Conference.
H.C. Wainwright analyst Patrick Trucchio stated that the discussion reinforced Vir’s dual-franchise strategy, which focuses on near-term execution of the T-cell engager (TCE) oncology platform priorities.
The analyst also noted the company’s emphasis on long-term value creation from its late-stage hepatitis delta virus (HDV) program.
The firm’s $15 price target for Vir Biotechnology remains unchanged following the management meeting at the investment conference.
In other recent news, Vir Biotechnology reported its second-quarter earnings for 2025, which showed a larger-than-expected loss and a significant revenue shortfall. The company reported an earnings per share of -0.8 USD, compared to the forecasted -0.7 USD, marking a 14.29% negative surprise. Revenue was reported at 1.21 million USD, falling well below the anticipated 2.66 million USD, resulting in a 54.51% negative surprise. In addition, BofA Securities upgraded Vir Biotechnology from Neutral to Buy, raising the price target to $14.00 from $12.00. This upgrade reflects the firm’s belief in the potential of Vir’s treatment for severe liver disease caused by hepatitis delta virus, which could generate over $1 billion in unadjusted peak sales. Evercore ISI also initiated coverage on Vir Biotechnology with an Outperform rating, setting a price target of $12.00. The firm noted a "compelling asymmetric setup" for the company, highlighting the market’s lack of appreciation for its potential improvements. These developments indicate significant interest and varied perspectives from analysts regarding Vir Biotechnology’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.